Anesthesia; Reaction
Conditions
Keywords
Dexmedetomidine, Ketamine, Propofol, Sedation
Brief summary
Sedation with dexmedetomidine-propofol or ketamine-propofol was planned in patients with upper gastrointestinal endoscopy.
Detailed description
Patients between 18 and 60 years in American Society of Anesthesiologists (ASA) I and II groups were included. Patients that had severe organ disease, allergies to study drugs, refused to participate in the study were excluded. Cases were randomized into the dexmedetomidine-propofol group (Group D, n=30) and ketamine-propofol group (Group K, n=30). Cardiac monitoring, peripheral oxygen saturation, bispectral index (BIS) monitoring were performed. Group D received 1mg/kg dexmedetomidine+0.5mg/kg propofol intravenous (iv) bolus, 0.5 μg/kg/h dexmedetomidine+ 0.5 mg/kg/h propfol infusion. Group K received 0.125 mL/kg bolus, 0.125 mL/kg/h ketamine+ propofol = ketofol infusion (ketofol was prepared with 4 mg propofol+2 mg ketamine). Patients were followed up with a Ramsay Sedation Scale (RSS) of≥4. Mean, standard deviation, mean, lowest-highest frequency and ratio values were used in descriptive statistics of the data, SPSS 22.0 program was used for the analyses.
Interventions
DRUGDexmedetomidine
Group D received 1mg/kg dexmedetomidine+0.5mg/kg propofol intravenous (iv) bolus, 0.5 μg/kg/h dexmedetomidine+ 0.5 mg/kg/h propfol infusion. Group K received 0.125 mL/kg bolus, 0.125 mL/kg/h ketamine+ propofol = ketofol infusion (ketofol was prepared with 4 mg propofol+2 mg ketamine).
Sponsors
Yuzuncu Yil University
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* ASA I-II group * 60 patients * between the ages of 18 and 60 * planned to have upper gastrointestinal system (UGIS) endoscopy with sedation,
Exclusion criteria
* severe heart, lung, liver disease * kidney failure, * bleeding diathesis * fever, * infection, * electrolyte disorder such as hypokalemia, hypocalcaemia, acid-base disorder, hypothermia, allergy to drugs to be used, and study those who refused to be included were excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Demographic data | 2 minutes | no difference |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| adverse events | 2 minutes | Nausea, vomiting and allergic reaction, cough |
Other
| Measure | Time frame | Description |
|---|---|---|
| sedation depth | 2 minutes | Measured with BIS |
Countries
Turkey (Türkiye)
Outcome results
None listed